AIIMS administers first dose of COVID-19 candidate vaccine `Covaxin’ to 30-year-old Delhi resident
First Published: 25th July, 2020 15:18 IST
The All India Institute of Medical Sciences (AIIMS) on Friday administered the first dose of country’s first indigenous vaccine candidate `Covaxin’ to a 30-year-old man as part of efforts to
The All India Institute of Medical Sciences (AIIMS) on Friday administered the first dose of country’s first indigenous vaccine candidate `Covaxin’ to a 30-year-old man as part of efforts to combat COVID-19.
This is the first phase of human clinical trial after the institute’s ethics committee gave its approval for the trail for the indigenously developed COVID-19 vaccine candidate Covaxin.
Prof (Dr) Sanjay Rai, who works in the Community Medicine Department and is principal investigator of the study, said that dose was administered to a resident of Delhi.
“Today, we administered the first dose of Covaxin to a 30-year-old man, the first volunteer, who is a resident of Delhi. He was screened two days ago and all his health vital parameters were normal. He does not have any co-morbid conditions or any pre-existing illness,” Dr Rai told ANI.
“Post-vaccination, the subject was in close observation for two hours. There was no sudden side-effect observed. The subject will be monitored for a week,” he said.
Dr Rai said more than 3,500 volunteers have already registered for the trial at AIIMS
“Screening for 22 subjects is ongoing and only about a third of them were found to have normal parameters. More volunteers will be vaccinated tomorrow once their health screening reports come,” he said.
The patient has been provided with a health card for noting down his daily medical condition and has also been asked to maintain his daily routine. The doctors will check up his health condition daily through telephone for one week post the administration of the vaccine.
According to the Indian Council for Medical Research (ICMR), the trial is taking place at 12 sites for phase I and II randomised, double-blind, placebo-controlled clinical trials of Covaxin.
Apart from AIIMS Delhi, trial is taking place at AIIMS Patna and few other sites.
“Any healthy individual who wishes to participate in the trial can send in an email on [email protected] or send an SMS or call on 7428847499,” the AIIMS doctor said adding that for phases I & II phase- AIIMS (Delhi) will choose only 100 participants out of 375 volunteers and remaining participants will be studied at other sites.
The top drug regulator had earlier given its green signal for human clinical trials for Covaxin, which has been developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), Pune. (ANI)
COMMENTS
TOPMOST STORY NOW
Live Assam CM Pledges to Eradicate Child Marriage by 2026; Over 2,000 Arrested in Crackdown So Far
23rd December 2024Live “Kuwait’s highest civilian honour recognises PM Modi’s leadership in strengthening India-Gulf ties”: EAM Jaishankar
23rd December 2024Live Small plane crashes into Brazilian city, killing at least 10 people
23rd December 2024Live Assam Shocker: Tiger Kills Man, Eats His Body Parts
22nd December 2024WE RECOMMEND
7 Indian nationals injured in Magdeburg Christmas market attack
Of these,three have been discharged from the hospital, while the Indian Mission is closely monitoring the condition of the remaining victims.
22nd December 2024Nagaland MP Accuses Rahul Gandhi of Standing Too Close to Her, Making Her Feel Uncomfortable
MP Phangnon Konyak has filed a complaint with Rajya Sabha Chairman against Congress leader Rahul Gandhi
19th December 2024GRAP Stage IV reintroduced in NCR as AQI breaches 400 mark
This comes after the Air Quality Index in Delhi breached the 400 mark. AQI was recorded as 399 at 9 pm and 401 at 10 pm.
17th December 2024India, Bangladesh to commemorate 1971 war ‘Vijay Diwas’ with annual exchange of veterans today
The event also gave an opportunity to the tribal community to showcase their talent.
16th December 2024Would You Pay Rs 1 Lakh for Tea? Dubai’s Luxe ‘Gold Karak’ Has Everyone Talking. What Makes It So Special?
Served in a pure silver cup and topped with 24-carat edible gold leaf, it’s more than just a drink.
15th December 2024